Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease.

The inability to effectively halt or cure Alzheimer's disease (AD), exacerbated by the recent failures of high-profile clinical trials, emphasizes the urgent need to understand the complex biochemistry of this major neurodegenerative disease. In this paper, ten central, current challenges of the major paradigm in the field, the amyloid hypothesis, are sharply formulated. These challenges together show that new approaches are necessary that address data heterogeneity, increase focus on the proteome level, use available human patient data more actively, account for the aging phenotype as a background model of the disease, unify our understanding of the interplay between genetic and non-genetic risk factors, and combine into one framework both the familial and sporadic forms of the disease.

[1]  C. Peers,et al.  Physiological roles for amyloid beta peptides. , 2006, The Journal of physiology.

[2]  Ashley I. Bush,et al.  Therapeutics for Alzheimer’s disease based on the metal hypothesis , 2008, Neurotherapeutics.

[3]  L. Villa-komaroff,et al.  Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. , 1989, Science.

[4]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[5]  Y. Mimori,et al.  Association Between Dementia and Midlife Risk Factors: the Radiation Effects Research Foundation Adult Health Study , 2003, Journal of the American Geriatrics Society.

[6]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.

[7]  C. Masters,et al.  The familial occurrence of Creutzfeldt-Jakob disease and Alzheimer's disease. , 1981, Brain : a journal of neurology.

[8]  Kenjiro Ono,et al.  Structure–neurotoxicity relationships of amyloid β-protein oligomers , 2009, Proceedings of the National Academy of Sciences.

[9]  T. Suuronen,et al.  Inflammation in Alzheimer's disease: Amyloid-β oligomers trigger innate immunity defence via pattern recognition receptors , 2009, Progress in Neurobiology.

[10]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[11]  Kayalvili Sanmugam Depression is a Risk Factor for Alzheimer Disease- Review , 2015 .

[12]  Miguel Ángel Martínez,et al.  Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. , 1997, American journal of human genetics.

[13]  B. de Strooper,et al.  Loss‐of‐function presenilin mutations in Alzheimer disease , 2007, EMBO reports.

[14]  Karl Herrup,et al.  The case for rejecting the amyloid cascade hypothesis , 2015, Nature Neuroscience.

[15]  X. Chen,et al.  Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease , 2005 .

[16]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[17]  George B. Benedek,et al.  Kinetic theory of fibrillogenesis of amyloid β-protein , 1997 .

[18]  F. Tarazi,et al.  Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive? , 2013, Expert opinion on biological therapy.

[19]  Xiongwei Zhu,et al.  Alzheimer's disease: the two-hit hypothesis , 2004, The Lancet Neurology.

[20]  R. Nitrini,et al.  Oral Infections and Cytokine Levels in Patients with Alzheimer's Disease and Mild Cognitive Impairment Compared with Controls. , 2016, Journal of Alzheimer's disease : JAD.

[21]  S. Lipton,et al.  Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-d-aspartate receptors , 2012, Proceedings of the National Academy of Sciences.

[22]  Meng Zhang,et al.  A study on the association between infectious burden and Alzheimer's disease , 2015, European journal of neurology.

[23]  E. Siemers,et al.  Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease , 2012, Alzheimer's & Dementia.

[24]  M. Wolfe Processive proteolysis by γ-secretase and the mechanism of Alzheimer’s disease , 2012, Biological chemistry.

[25]  L. Donini,et al.  Nutritional status determinants and cognition in the elderly. , 2007, Archives of gerontology and geriatrics.

[26]  K. P. Kepp,et al.  The Dependence of Amyloid-β Dynamics on Protein Force Fields and Water Models. , 2015, Chemphyschem : a European journal of chemical physics and physical chemistry.

[27]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[28]  A. Goate,et al.  Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis , 2015, Biological Psychiatry.

[29]  K. Moore,et al.  The NALP3 inflammasome is involved in the innate immune response to amyloid-β , 2008, Nature Immunology.

[30]  I. Kohane,et al.  Gene regulation and DNA damage in the ageing human brain , 2004, Nature.

[31]  I. Slutsky,et al.  Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses , 2009, Nature Neuroscience.

[32]  O. Almkvist,et al.  Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease , 2003, Acta neurologica Scandinavica. Supplementum.

[33]  Kye Y. Kim,et al.  Risk factors for Alzheimer's disease: an overview for clinical practitioners. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[34]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[35]  Mark A. Smith,et al.  Alzheimer Disease and Oxidative Stress , 2002, Journal of biomedicine & biotechnology.

[36]  Richard I. Morimoto,et al.  Adapting Proteostasis for Disease Intervention , 2008, Science.

[37]  Richard Mayeux,et al.  Epidemiology of neurodegeneration. , 2003, Annual review of neuroscience.

[38]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[39]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[40]  Hilkka Soininen,et al.  Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. , 2005, Archives of neurology.

[41]  C. Glabe Common mechanisms of amyloid oligomer pathogenesis in degenerative disease , 2006, Neurobiology of Aging.

[42]  Ottavio Arancio,et al.  Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? , 2012, The Biochemical journal.

[43]  A. Palmeri,et al.  Rodent models for Alzheimer’s disease drug discovery , 2015, Expert opinion on drug discovery.

[44]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[45]  K. P. Kepp,et al.  Bioinorganic chemistry of Alzheimer's disease. , 2012, Chemical reviews.

[46]  P. Steiner,et al.  Molecular Mechanisms of Alzheimer Disease Protection by the A673T Allele of Amyloid Precursor Protein* , 2014, The Journal of Biological Chemistry.

[47]  R. Nanga,et al.  Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity , 2010, Proceedings of the National Academy of Sciences.

[48]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[49]  M. Tiwari,et al.  β-Amyloid pathogenesis: Chemical properties versus cellular levels , 2016, Alzheimer's & Dementia.

[50]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. , 2006, Journal of Alzheimer's disease : JAD.

[51]  K. P. Kepp,et al.  Direct Correlation of Cell Toxicity to Conformational Ensembles of Genetic Aβ Variants. , 2015, ACS chemical neuroscience.

[52]  R. Castellani,et al.  Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. , 2012, Archives of medical research.

[53]  A. Hofman,et al.  Non-insulin-dependent Diabetes Mellitus (niddm) Association of Diabetes Mellitus and Dementia: the Rotterdam Study , 2022 .

[54]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[55]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[56]  K. Yaffe,et al.  The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.

[57]  K. P. Kepp,et al.  Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer's disease , 2016, Journal of neurochemistry.

[58]  W. Banks,et al.  A Physiological Role for Amyloid-β Protein: Enhancement of Learning and Memory , 2010 .

[59]  S. Hébert,et al.  Differential contribution of the three Aph1 genes to γ-secretase activity in vivo , 2005 .

[60]  J. Busciglio,et al.  Different Conformations of Amyloid β Induce Neurotoxicity by Distinct Mechanisms in Human Cortical Neurons , 2006, The Journal of Neuroscience.

[61]  K. Blennow,et al.  Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[62]  L. Bäckman,et al.  Multiple cognitive deficits during the transition to Alzheimer's disease , 2004, Journal of internal medicine.

[63]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[64]  R. Kane,et al.  Conformational Differences between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity* , 2012, The Journal of Biological Chemistry.

[65]  J. Quinn,et al.  Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. , 2006, Human molecular genetics.

[66]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[67]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[68]  J. Gilthorpe,et al.  Reactivated herpes simplex infection increases the risk of Alzheimer's disease , 2015, Alzheimer's & Dementia.

[69]  F. Barkhof,et al.  Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003) , 2016 .

[70]  Robert A. Dean,et al.  Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.

[71]  D. Selkoe,et al.  Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.

[72]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[73]  Xi Chen,et al.  Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A␤ to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .

[74]  J. Galvin,et al.  Distinguishing Alzheimer’s disease from other major forms of dementia , 2011, Expert review of neurotherapeutics.

[75]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[76]  M. Matamales,et al.  Modes of Aβ toxicity in Alzheimer’s disease , 2011, Cellular and Molecular Life Sciences.

[77]  Ayyalusamy Ramamoorthy,et al.  Two-step mechanism of membrane disruption by Aβ through membrane fragmentation and pore formation. , 2012, Biophysical journal.

[78]  K. Zou,et al.  A Novel Function of Monomeric Amyloid β-Protein Serving as an Antioxidant Molecule against Metal-Induced Oxidative Damage , 2002, The Journal of Neuroscience.

[79]  K. P. Kepp,et al.  The dynamic mechanism of presenilin-1 function: Sensitive gate dynamics and loop unplugging control protein access , 2016, Neurobiology of Disease.

[80]  C. Peers,et al.  Physiological roles for amyloid β peptides , 2006 .

[81]  R. Nitrini,et al.  Oral Infections and Cytokine Levels in Patients with Alzheimer's Disease and Mild Cognitive Impairment Compared with Controls. , 2016, Journal of Alzheimer's disease : JAD.

[82]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[83]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[84]  Ashley I. Bush,et al.  Dietary and lifestyle guidelines for the prevention of Alzheimer's disease , 2014, Neurobiology of Aging.

[85]  Mark P Mattson,et al.  Antiparallel β-sheet architecture in Iowa-mutant β-amyloid fibrils , 2012, Proceedings of the National Academy of Sciences.

[86]  G. Eslick,et al.  BACTERIAL INFECTION AND ALZHEIMER'S DISEASE: A META-ANALYSIS , 2014, Alzheimer's & Dementia.

[87]  C. Peers,et al.  The Production of Amyloid β Peptide Is a Critical Requirement for the Viability of Central Neurons , 2003, The Journal of Neuroscience.

[88]  Guy D. Eslick,et al.  BACTERIAL INFECTION AND ALZHEIMER'S DISEASE: A META-ANALYSIS , 2014, Alzheimer's & Dementia.

[89]  W. Rosenblum Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult , 2014, Neurobiology of Aging.

[90]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[91]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[92]  F. Fabris,et al.  Risk factors for dementia of Alzheimer's type: a case-control, retrospective evaluation. , 2001, Archives of gerontology and geriatrics. Supplement.

[93]  Wiesje M. van der Flier,et al.  CSF biomarker levels in early and late onset Alzheimer's disease , 2009, Neurobiology of Aging.

[94]  Alyssa A. Gamaldo,et al.  Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis , 2014, BMC Public Health.

[95]  Kasper P. Kepp,et al.  A Model of Proteostatic Energy Cost and Its Use in Analysis of Proteome Trends and Sequence Evolution , 2014, PloS one.

[96]  A Hofman,et al.  Relation between smoking and risk of dementia and Alzheimer disease , 2007, Neurology.

[97]  Rusha Shah The role of nutrition and diet in Alzheimer disease: a systematic review. , 2013, Journal of the American Medical Directors Association.

[98]  R. Lal,et al.  Fresh and globular amyloid β protein (1–42) induces rapid cellular degeneration: evidence for AβP channel‐mediated cellular toxicity , 2000 .

[99]  B. de Strooper,et al.  The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.

[100]  N. Calcutt,et al.  The pathological interaction between diabetes and presymptomatic Alzheimer's disease , 2009, Neurobiology of Aging.

[101]  Hugo Vanderstichele,et al.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.

[102]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[103]  D. Kirschner,et al.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.

[104]  R. J. Kelleher,et al.  The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism , 2007, Proceedings of the National Academy of Sciences.

[105]  Roger M. Nitsch,et al.  Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study , 2015, Alzheimer's & Dementia.

[106]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[107]  Z. Janka,et al.  Risk factors of cognitive decline in residential care in Hungary , 2007, International journal of geriatric psychiatry.

[108]  Hai Lin,et al.  Amyloid ion channels: a common structural link for protein-misfolding disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[109]  V. Papadopoulos,et al.  Beta-Amyloid and Oxidative Stress Jointly Induce Neuronal Death, Amyloid Deposits, Gliosis, and Memory Impairment in the Rat Brain , 2005, Pharmacology.

[110]  M. Tiwari,et al.  Pathogenic properties of Alzheimer's β-amyloid identified from structure-property patient-phenotype correlations. , 2015, Dalton transactions.

[111]  J. Brender,et al.  Membrane disordering is not sufficient for membrane permeabilization by islet amyloid polypeptide: studies of IAPP(20-29) fragments. , 2013, Physical chemistry chemical physics : PCCP.

[112]  K. Yaffe,et al.  Body mass index in midlife and risk of Alzheimer disease and vascular dementia. , 2007, Current Alzheimer research.

[113]  B. de Strooper,et al.  Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015, Annual review of pharmacology and toxicology.

[114]  D. Selkoe,et al.  Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.

[115]  K. Morgan,et al.  Review: The genetics of Alzheimer's disease; putting flesh on the bones , 2014, Neuropathology and applied neurobiology.

[116]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[117]  H. Lin,et al.  Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[118]  Michael J Owen,et al.  Alzheimer's disease genetics: current knowledge and future challenges , 2011, International journal of geriatric psychiatry.

[119]  M. Woodward Prevention of Alzheimer's Disease and Other Dementias , 2003 .

[120]  J. Hardy,et al.  A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease , 2014, Annals of neurology.

[121]  J. Karlawish Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease , 2011, Neurology.

[122]  C. Dufouil,et al.  Cardiovascular risk profile in women and dementia. , 2014, Journal of Alzheimer's Disease.

[123]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[124]  L. Jungbauer,et al.  Preparing synthetic Aβ in different aggregation states. , 2011, Methods in molecular biology.

[125]  Ronald C Petersen,et al.  Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. , 2014, Journal of Alzheimer's disease : JAD.

[126]  D. Selkoe,et al.  Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.

[127]  D. Na,et al.  Systematic review of health behavioral risks and cognitive health in older adults , 2009, International Psychogeriatrics.

[128]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[129]  Nick C Fox,et al.  Symptom onset in autosomal dominant Alzheimer disease , 2014, Neurology.

[130]  G. Sorrentino,et al.  The dark sides of amyloid in Alzheimer's disease pathogenesis , 2014, FEBS letters.

[131]  E. Rojas,et al.  Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[132]  D. Drachman The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[133]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[134]  H. Steinbusch,et al.  Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. , 2004, The American journal of pathology.

[135]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[136]  T. Stijnen,et al.  Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis , 2014, Alzheimer's & Dementia.

[137]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[138]  P. Fraering,et al.  Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified γ-Secretase Complexes , 2012, PloS one.

[139]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[140]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[141]  A. Ramamoorthy,et al.  Structural characterization and inhibition of toxic amyloid-β oligomeric intermediates. , 2013, Biophysical journal.

[142]  J. Miklossy Emerging roles of pathogens in Alzheimer disease , 2011, Expert Reviews in Molecular Medicine.

[143]  R. Deane,et al.  Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. , 2007, Current Alzheimer research.

[144]  B. Hyman,et al.  The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide , 2010, PloS one.

[145]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[146]  Sara Linse,et al.  A facile method for expression and purification of the Alzheimer’s disease-associated amyloid β-peptide , 2009, The FEBS journal.

[147]  Albert Hofman,et al.  Alcohol consumption and risk of dementia: the Rotterdam Study , 2002, The Lancet.

[148]  M. Tiwari,et al.  Modeling the Aggregation Propensity and Toxicity of Amyloid-β Variants. , 2015, Journal of Alzheimer's disease : JAD.

[149]  Lars Bertram,et al.  Genome-wide association studies in Alzheimer's disease. , 2009, Human molecular genetics.

[150]  H. Lashuel,et al.  The Ratio of Monomeric to Aggregated Forms of Aβ40 and Aβ42 Is an Important Determinant of Amyloid-β Aggregation, Fibrillogenesis, and Toxicity* , 2008, Journal of Biological Chemistry.

[151]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[152]  D. Kirschner,et al.  Kinetic theory of fibrillogenesis of amyloid beta-protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[153]  Minna Rusanen,et al.  Leisure-time physical activity from mid- to late life, body mass index, and risk of dementia , 2015, Alzheimer's & Dementia.

[154]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[155]  B. Dubois,et al.  Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. , 1999, American journal of human genetics.

[156]  B. Strooper,et al.  Lessons from a Failed γ-Secretase Alzheimer Trial , 2014, Cell.

[157]  J. Treanor,et al.  Title beta-secretase cleavage of Alzheimer ' s amyloid precursor protein by the transmembrane aspartic protease , 2015 .